COVID-19, how to treat the disease during Fall 2022?
Since the arrival of COVID-19, we have witnessed a series of new variants and new therapies, and it is therefore becoming difficult to stay up to date on the best management of an outpatient infected with SARS-CoV-2. In a patient at risk of an unfavorable evolution in the first 5 days of illness, the antiviral Paxlovid is recommended. Evusheld, administered in the hospitals, is recommended in patients with a documented negative serology, for treatment in early disease or as a pre-exposure prophylaxis. The activity of monoclonal antibodies seems to be reduced with the new variants. Dexamethasone is reserved for the hospital management of an oxygen-dependent patient. There is no place for antibiotic therapy apart from additional bacterial infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Revue medicale suisse - 18(2022), 802 vom: 02. Nov., Seite 2077-2081 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Covid-19 : quelle prise en charge pour l’automne 2022 ? |
|---|
| Beteiligte Personen: |
Chollet, Vincent [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 07.11.2022 Date Revised 07.11.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.53738/REVMED.2022.18.802.2077 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348401884 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348401884 | ||
| 003 | DE-627 | ||
| 005 | 20231226040112.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.53738/REVMED.2022.18.802.2077 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348401884 | ||
| 035 | |a (NLM)36326227 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Chollet, Vincent |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19, how to treat the disease during Fall 2022? |
| 246 | 3 | 3 | |a Covid-19 : quelle prise en charge pour l’automne 2022 ? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.11.2022 | ||
| 500 | |a Date Revised 07.11.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Since the arrival of COVID-19, we have witnessed a series of new variants and new therapies, and it is therefore becoming difficult to stay up to date on the best management of an outpatient infected with SARS-CoV-2. In a patient at risk of an unfavorable evolution in the first 5 days of illness, the antiviral Paxlovid is recommended. Evusheld, administered in the hospitals, is recommended in patients with a documented negative serology, for treatment in early disease or as a pre-exposure prophylaxis. The activity of monoclonal antibodies seems to be reduced with the new variants. Dexamethasone is reserved for the hospital management of an oxygen-dependent patient. There is no place for antibiotic therapy apart from additional bacterial infection | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Manuel, Oriol |e verfasserin |4 aut | |
| 700 | 1 | |a De Vallière, Serge |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale suisse |d 2005 |g 18(2022), 802 vom: 02. Nov., Seite 2077-2081 |w (DE-627)NLM154244252 |x 1660-9379 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:802 |g day:02 |g month:11 |g pages:2077-2081 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.53738/REVMED.2022.18.802.2077 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 802 |b 02 |c 11 |h 2077-2081 | ||